Targeted radiation zaps prostate cancer in new trial
NCT ID NCT04663997
Summary
This study is testing whether a new targeted radiation drug called 177Lu-PSMA-617 can slow the growth of advanced prostate cancer better than the standard chemotherapy drug, docetaxel. It is for men whose cancer has spread and is no longer responding to standard hormone-blocking treatments. Participants are randomly assigned to receive either the new radiation therapy or the standard chemotherapy to directly compare their effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 3E4, Canada
-
CIUSSS de l'Estrie - Centre hospitalier
Sherbrooke, Quebec, J1H 5N4, Canada
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Hotel-Dieu de Quebec
Québec, Quebec, G1R 2J6, Canada
-
London Regional Cancer Program
London, Ontario, N6A 5W9, Canada
-
Odette Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
-
The Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.